Search results for "Adverse effect"

showing 10 items of 1065 documents

Prevalence and correlates of QTc prolongation in Italian psychiatric care: cross-sectional multicentre study.

2016

Aims.In recent years several warnings have been issued by regulatory authorities on the risk of electrocardiogram abnormalities in individuals exposed to psychotropic drugs. As a consequence of these warnings, monitoring of the QT interval corrected for heart rate (QTc) has become increasingly common. This study was conducted to measure the frequency of QTc prolongation in unselected psychiatric patients, and to document the associated factors using a cross-sectional approach.Method.The study was carried out in 35 Italian psychiatric services that are part of the STAR (Servizi Territoriali Associati per la Ricerca) Network, a research group established to produce scientific knowledge by col…

AdultMalemedicine.medical_specialtyPsychotropic drugsEpidemiologymedicine.medical_treatmentLong QT syndromeAntidepressantDrug overdoseAdverse effectQT intervalAntipsychotic03 medical and health sciencesElectrocardiography0302 clinical medicineRisk FactorsPsychotropic drugmedicinePrevalenceHumanscardiovascular diseasesAntipsychoticAdverse effectPsychiatrySettore MED/25 - PsichiatriaPolypharmacybusiness.industryEnvironmental and Occupational HealthPublic Health Environmental and Occupational HealthAdverse effect; Antidepressant; Antipsychotic; Psychotropic drugs; Epidemiology; Public Health; Environmental and Occupational Health; Psychiatry and Mental HealthOriginal Articlesmedicine.diseaseAdverse effect; Antidepressant; Antipsychotic; Psychotropic drugs; Epidemiology; Public Health Environmental and Occupational Health; Psychiatry and Mental Health030227 psychiatrySubstance abuseLong QT SyndromeCross-Sectional StudiesItalyPsychiatry and Mental HealthPolypharmacyAripiprazoleFemalePublic HealthbusinessAntidepressant; adverse effect; antipsychotic; psychotropic drugsAdverse effect; Antidepressant; Antipsychotic; Psychotropic drugs; Adult; Antipsychotic Agents; Cross-Sectional Studies; Electrocardiography; Female; Humans; Italy; Long QT Syndrome; Male; Prevalence; Risk Factors; Polypharmacy; Epidemiology; Public Health Environmental and Occupational Health; Psychiatry and Mental Health030217 neurology & neurosurgerymedicine.drugAntipsychotic AgentsEpidemiology and psychiatric sciences
researchProduct

Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial.

2018

Current treatments for long-term prophylaxis in hereditary angioedema have limitations.To assess the efficacy of lanadelumab, a fully human monoclonal antibody that selectively inhibits active plasma kallikrein, in preventing hereditary angioedema attacks.Phase 3, randomized, double-blind, parallel-group, placebo-controlled trial conducted at 41 sites in Canada, Europe, Jordan, and the United States. Patients were randomized between March 3, 2016, and September 9, 2016; last day of follow-up was April 13, 2017. Randomization was 2:1 lanadelumab to placebo; patients assigned to lanadelumab were further randomized 1:1:1 to 1 of the 3 dose regimens. Patients 12 years or older with hereditary a…

AdultMalemedicine.medical_specialtyRandomizationAdolescentInjections SubcutaneousLanadelumabPlaceboAntibodies Monoclonal Humanizedlaw.invention03 medical and health sciencesYoung Adult0302 clinical medicineRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineHumans030212 general & internal medicineYoung adultAdverse effectChildPlasma KallikreinAgedHereditary Angioedema Types I and IIbusiness.industryAntibodies MonoclonalCorrectionGeneral MedicineMiddle Agedmedicine.diseaseClinical trial030228 respiratory systemHereditary angioedemaQuality of LifeFemalebusinessJAMA
researchProduct

Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassemia major patients: a randomised clinical trial

2009

A multicentre randomized open-label trial was designed to assess the effectiveness of long-term sequential deferiprone–deferoxamine (DFO–DFP) versus DFP alone to treat thalassaemia major (TM). DFP at 75 mg/kg, divided into three oral daily doses, for 4 d/week and DFO by subcutaneous infusion (8–12 h) at 50 mg/kg per day for the remaining 3 d/week was compared with DFP alone at 75 mg/kg, administered 7 d/week during a 5-year follow-up. The main outcome measures were differences between multiple observations of serum ferritin concentrations. Secondary outcomes were survival analysis, adverse events, and costs. Consecutive thalassaemia patients (275) were assessed for eligibility; 213 of these…

AdultMalemedicine.medical_specialtyRandomizationAdolescentPyridonesAdministration OralKaplan-Meier EstimateDeferoxamineInfusions SubcutaneousIron Chelating AgentsGastroenterologylaw.inventionYoung Adultchemistry.chemical_compoundRandomized controlled triallawInternal medicinemedicineHumansDeferiproneAdverse effectDecreased serum ferritinSurvival analysisbusiness.industryHematologySurgeryClinical trialDeferoxamineChelation thalassaemia clinical trials red blood cell disorders iron overload.Treatment OutcomechemistryFerritinsThalassemiaDrug Therapy CombinationFemalebusinessDeferiproneFollow-Up Studiesmedicine.drug
researchProduct

Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholeste…

2017

Homozygous familial hypercholesterolemia is a genetic disorder characterized by low-density lipoprotein (LDL)-receptor dysfunction, markedly elevated levels of LDL-cholesterol (LDL-C) and premature atherosclerosis. Patients are often poorly responsive to conventional lipid-lowering therapies that upregulate LDL-receptor expression.1 Lomitapide inhibits microsomal triglyceride transfer protein, which lipidates nascent apolipoprotein (apo)B-containing lipoproteins. In a pivotal 78-week open-label trial, lomitapide, titrated to the maximal tolerable dose, decreased LDL-C by 50% at the end of the efficacy phase (week 26) in patients with homozygous familial hypercholesterolemia.2 The principal …

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein BSocio-culturaleFamilial hypercholesterolemia030204 cardiovascular system & hematologyGastroenterologyMicrosomal triglyceride transfer proteinLDLTimeSudden cardiac deathHyperlipoproteinemia Type II03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePhysiology (medical)Internal medicinemedicineHumans030212 general & internal medicineAdverse effectlomitapidebiologybusiness.industryCholesterolAnticholesteremic AgentsCholesterol LDLlomitapide; Adult; Anticholesteremic Agents; Benzimidazoles; Carrier Proteins; Cholesterol LDL; Female; Humans; Hyperlipoproteinemia Type II; Male; Timemedicine.diseaseLomitapideCholesterolEndocrinologychemistrybiology.proteinBenzimidazolesFemalelipids (amino acids peptides and proteins)lomitapide; Cardiology and Cardiovascular Medicine; Physiology (medical)Carrier ProteinsCardiology and Cardiovascular MedicinebusinessLipoproteinCirculation
researchProduct

Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Si…

2020

BACKGROUND AND OBJECTIVE: Older people with inflammatory bowel disease (IBD) appear to have a lower response to anti-tumour necrosis factor (TNF) therapy, with more frequent complications than younger patients. The objective of this study was to assess persistence on therapy and the safety of anti-TNF therapy in older patients (aged ≥ 60 years). METHODS: We retrospectively reviewed the database of the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD), extracting data regarding IBD patients aged ≥ 60 years and controls < 60 years of age at their first course of anti-TNF treatment. Data concerning persistence on therapy over the first year of treatment (primary objective) together …

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaDrug-Related Side Effects and Adverse ReactionsKaplan-Meier EstimateAnti-Tumour Necrosis FactorDiseaseInflammatory bowel diseaseCohort Studies03 medical and health sciences0302 clinical medicinePharmacotherapyInternal medicinemedicineHumansPharmacology (medical)Treatment Failure030212 general & internal medicineAdverse effectAgedRetrospective StudiesAged 80 and overTumor Necrosis Factor-alphabusiness.industryInflammatory Bowel DiseaseAdalimumabAge FactorsAntibodies MonoclonalRetrospective cohort studyMiddle AgedInflammatory Bowel Diseasesmedicine.diseaseUlcerative colitisInfliximabSicilian Network for Inflammatory Bowel Diseases (SN-IBD).Withholding TreatmentConcomitantFemaleGeriatrics and Gerontologybusiness030217 neurology & neurosurgeryCohort studyDrugs & Aging
researchProduct

Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia.

2014

The microsomal triglyceride transfer protein (MTP) inhibitor lomitapide is a licenced adjunct to a low-fat diet and other lipid-lowering medication, with or without low-density lipoprotein apheresis, for the treatment of adults with homozygous familial hypercholesterolaemia (HoFH). In a recently published phase 3 study, patients with HoFH received lomitapide in addition to maximally tolerated lipid-lowering therapy. Treatment with lomitapide resulted in a mean approximate 50% reduction in LDL-C levels after 26 weeks compared with baseline levels (p < 0.0001). This decrease in LDL-C was maintained at Weeks 56 and 78 (44% [p < 0.0001] and 38% [p = 0.0001], respectively). This paper offers cli…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaPhases of clinical researchMicrosomal triglyceride transfer proteinHyperlipoproteinemia Type IIchemistry.chemical_compoundYoung AdultInternal medicineHo-FH lomitapide MTPInternal MedicinemedicineEffective treatmentHumansIn patientAdverse effectbiologymedicine.diagnostic_testbusiness.industryAnticholesteremic AgentsHomozygoteGeneral MedicineCholesterol LDLMiddle AgedLomitapideEndocrinologyApheresisTreatment Outcomechemistrybiology.proteinBenzimidazolesFemaleCardiology and Cardiovascular MedicinebusinessLiver function testsAtherosclerosis. Supplements
researchProduct

Beclomethasone dipropionate in Crohn's ileitis: A randomised, double-blind trial.

2011

Abstract Background Steroids, the mainstay of Crohn's disease treatment, have been associated with systemic side effects. Aim To evaluate the efficacy and tolerability of beclomethasone dipropionate for maintaining remission induced by a short course of systemic steroids in patients with Crohn's ileitis with or without right colonic involvement. Methods Patients (n = 84) with active Crohn's disease who achieved remission during a 2-week prednisone run-in period were randomised to receive beclomethasone dipropionate for 24 weeks or continue prednisone for a further 2 weeks followed by placebo for 22 weeks. The primary outcome was relapse rate (Crohn's Disease Activity Index score > 150 and a…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaRemissionKaplan-Meier EstimateBeclomethasone dipropionate Crohn's disease RemissionPlaceboGastroenterologyDrug Administration ScheduleMedication Adherencelaw.inventionDouble blindCrohn DiseaseDouble-Blind MethodRandomized controlled triallawPrednisoneInternal medicineSecondary PreventionmedicineHumansIleitisAdverse effectGlucocorticoidsAgedCrohn's diseaseHepatologybusiness.industryRemission InductionBeclomethasoneGastroenterologyBeclomethasone dipropionate Crohn's ileitis:.Middle Agedmedicine.diseaseSurgeryBeclomethasone dipropionateCrohn's diseaseTreatment OutcomeTolerabilityPrednisoneFemaleTablets Enteric-Coatedbusinessmedicine.drug
researchProduct

Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain

2015

Purpose: The aim of the present study was to assess the long-term tolerability and efficacy of intranasal fentanyl (INFS) in opioid-tolerant patients with breakthrough cancer pain (BTP).Patients and methods: A 6 months, observational, prospective, cohort study design was employed to follow advanced cancer patients with BTP receiving INFS under routine clinical practice. Eligible adult cancer patients suffering from BTP had been prescribed INFS at effective doses. Data were collected at T0 and at month intervals for six months. The principal outcomes were the evaluation of possible serious adverse effects with prolonged use of INFS, the efficacy of BTP treatment with INFS, the quality of sle…

AdultMalemedicine.medical_specialtySettore MED/42 - Igiene Generale E ApplicataFentanylCohort StudiesPatient satisfactionNeoplasmsInternal medicineparasitic diseasesHumansPain ManagementMedicineProspective StudiesCancer painAdverse effectProspective cohort studyAdministration IntranasalAgedPain Measurementbusiness.industryBreakthrough PainMiddle AgedTolerabilityDiscontinuationAnalgesics OpioidFentanylBreakthrough pain; Cancer pain; Intranasal fentanyl; Tolerability; OncologyOncologyTolerabilityPatient SatisfactionAnesthesiaIntranasal fentanylFemaleSleepbusinessCancer painmedicine.drugCohort studySupportive Care in Cancer
researchProduct

Predicting Early and Sustained Virological Responses in Prior Nonresponders to Pegylated Interferon alpha-2b Plus Ribavirin Retreated With Peginterfe…

2013

GOALS: To evaluate the predictive value of complete early virological response (cEVR) on sustained virological response (SVR) following retreatment with peginterferon alpha-2a (40 kDa) plus ribavirin in previous nonresponders to peginterferon alpha-2b (12 kDa). BACKGROUND: In the randomized multinational retreatment with Pegasys in patients not responding to PegIntron therapy study, a 72-week regimen of peginterferon alpha-2a (40 kDa) plus ribavirin improved SVR rates over a standard 48-week regimen in previous nonresponders to peginterferon alpha-2b (12 kDa). cEVR, defined as hepatitis C virus RNA <50 IU/mL at treatment week 12, was an important predictor of SVR. STUDY: We conducted an exp…

AdultMalemedicine.medical_specialtyTime FactorsInterferon alpha-2Antiviral therapyAntiviral AgentsGastroenterologyPolyethylene Glycolslaw.inventionchemistry.chemical_compoundPharmacotherapyRandomized controlled trialnonresponderPredictive Value of TestslawInternal medicineRibavirinchronic hepatitis CHumansMedicinepeginterferonAdverse effectRandomized Controlled Trials as Topicbusiness.industryRibavirinGastroenterologyInterferon-alphavirus diseasesHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseasepeginterferon; chronic hepatitis C; nonresponder; retreatment; sustained virological responseRecombinant Proteinsdigestive system diseasesRegimenTreatment OutcomechemistryPredictive value of testsRelative riskRetreatmentDrug Therapy CombinationFemalesustained virological responsebusinessJournal of Clinical Gastroenterology
researchProduct

Electromyographic and Safety Comparisons of Common Lower Limb Rehabilitation Exercises for People With Hemophilia.

2020

Abstract Background Ankles and knees are commonly affected in people with hemophilia and thus are targets for prevention or rehabilitation. However, to our knowledge, no studies have evaluated muscle activity and safety during exercises targeting the lower limbs in people with hemophilia; this lack of information hinders clinical decision-making. Objective The aim of this study was to compare the tolerability of, safety of, and muscle activity levels obtained with external resistance (elastic or machine)-based and non–external resistance-based lower limb exercises in people with hemophilia. Design This was a cross-sectional study. Methods Eleven people who had severe hemophilia and were und…

AdultMalemedicine.medical_specialtyTime FactorsKnee Jointmedicine.medical_treatmentPhysical Therapy Sports Therapy and RehabilitationElectromyographyHemophilia ABicepsHemophilia BLower limb03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationHemarthrosismedicineHumans030212 general & internal medicineMuscle activityAdverse effectMuscle SkeletalRehabilitationExercise Tolerancemedicine.diagnostic_testbusiness.industryElectromyographyResistance TrainingExercise Therapymedicine.anatomical_structureCross-Sectional StudiesTolerabilityAnklebusiness030217 neurology & neurosurgeryAnkle JointPhysical therapy
researchProduct